Amgen Inc. (AMGN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
171.97+1.74 (+1.02%)
At close: 4:00 PM EDT
People also watch:
BIIBGILDCELGMRKBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open170.80
Prev Close170.23
Bid168.00 x 200
Ask175.01 x 300
Day's Range169.76 - 172.99
52wk Range130.09 - 176.64
1y Target EstN/A
Market Cap128.7B
P/E Ratio (ttm)17.60
Beta1.29
Volume2,735,779
Avg Vol (3m)2,907,642
Dividend & Yield4.00 (2.33%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • These Next-Generation Cholesterol Drugs Could Raise U.S. Healthcare Costs by $119 Billion a Year
    Motley Fool22 hours ago

    These Next-Generation Cholesterol Drugs Could Raise U.S. Healthcare Costs by $119 Billion a Year

    PCSK-9 inhibitors lowered LDL-C by roughly 60% in clinical trials, but do their costs far outweigh their benefits?

  • Benzinga2 days ago

    What Tidings From the Tetons? Long-Awaited Yellen Speech Today

    After a placid summer seldom interrupted by news of note, word comes down from Wyoming on Friday as Fed Chair Janet Yellen speaks. Speculation centers around what Yellen could say about potential rate ...

  • Barrons.com2 days ago

    [$$] Don't Expect an Amgen Breakup

    Amgen (AMGN:Nasdaq) Gabelli & Co. ($170.23, Aug. 26, 2016) We are initiating our coverage on Amgen with a Hold recommendation and a 2017 private market value of $190 per share. The revenue of Amgen’s legacy products is expected to decline at 4% compounded annualized growth rate (CAGR) through 2020 driven by biosimilar or generic erosion to Epogen, Aranesp, Neupogen, Neulasta and Sensipar. Amgen’s revenue from growth products is expected to grow at 16% CAGR, mainly driven by Xgeva/Prolia, Kyprolis and Repatha.